Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 319–324

doi: 10.17219/acem/78024

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Comorbidities in chronic obstructive pulmonary disease: Results of a national multicenter research project

Renata Rubinsztajn1,A,B,C,D,E,F, Tadeusz Przybyłowski1,A,B,C,D,E,F, Marcin Grabicki2,A,B,E, Krzysztof Karwat1,B,E, Marta Maskey-Warzęchowska1,B,E, Halina Batura-Gabryel2,A,B,E,F, Ryszarda Chazan1,A,C,D,E,F

1 Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland

2 Department of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, Poland

Abstract

Background. Chronic obstructive pulmonary disease (COPD) is associated with various comorbidities, which influence the course of COPD and worsen prognosis.
Objectives. The aim of this study was to analyze the comorbidities in a cohort of COPD patients in Poland during 12 months of observation.
Material and Methods. A total of 444 COPD patients (median age: 66.1 years) in all stages of airflow limitation severity were enrolled. Medical histories and a questionnaire concerning comorbidities were analyzed at baseline and after 12 months (data of 267 patients available). Anthropometric data, pulmonary function, and body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE index) were assessed.
Results. No comorbidities were reported in 9 patients (2.0%), 101 patients (22.7%) had 1–2 comorbidities, 243 (54.7%) had 3–5, and 91 (20.6%) had more than 5 comorbidities. Cardiovascular diseases (CVDs) were the most frequent ones, followed by peptic ulcer, obstructive sleep apnea (OSA), diabetes, gastroesophageal reflux disease (GERD), and osteoporosis; 11 patients had a history of lung cancer. Cachexia was observed in 11 cases, overweight in 136 cases and obesity in 139 cases. The incidence of CVDs increased with time. The number of comorbidities correlated with the body mass index (BMI) and the number of hospitalizations for extra-pulmonary causes, but not with airflow limitation. The BODE index score increased with the number of comorbidities.
Conclusion. In a cohort of Polish COPD patients, the most frequent comorbidities were CVDs. The number of comorbidities affected the BODE index, but not airflow limitation. The BODE index is better than forced expiratory volume in 1 s (FEV1) in the rating of COPD patients’ condition. The BMI correlated with the number of comorbidities as well as the number of hospitalizations for extra-pulmonary causes.

Key words

comorbidity, chronic obstructive pulmonary disease, cardiovascular disease, BODE index

References (35)

  1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: https://goldcopd.org. Accessed January 31, 2017.
  2. Alshabanal A, Zafari Z, Albanyan O, et al. Asthma and COPD Overlap Syndrome (ACOS): A systematic review and meta analysis. PLoS ONE. 2015;10:e0136065.
  3. Soler X, Gaio E, Powell FL, et al. High prevalence of obstructive sleep apnea in patients with moderate to severe COPD. Ann Am Thorac Soc. 2015;12:1219–1225.
  4. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: A case-control study in a health maintenance organization. Arch Intern Med. 2000;160:2653–2658.
  5. van Manen JG, Bindels PJ, IJzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54:287–293.
  6. Kinnunen T, Säynäjäkangas O, Tuuponen T, et al. Impact of comorbidities on the duration of COPD patients’ hospital episodes. Respir Med. 2003;97:143–146.
  7. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: Results from a longitudinal study. Lung. 2010; 188:321–329.
  8. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555.
  9. Rubinsztajn, R. Chazan R. Mortality and comorbidity in hospitalized chronic obstructive pulmonary disease patients. Pneumonol Alergol Pol. 2011;79:343–346.
  10. Koskela J, Kilpeläinen M, Kupiainen H, et al. Co-morbidities are the key nominator of the health-related quality of life in mild and moderate COPD. BMC Pulm Med. 2014;14:102. doi: 10.1186/1471-2466-14-102
  11. Sundh J, Johansson G, Larsson K, et al. Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. Int J Chron Obstruct Pulmon Dis. 2015;10:173–183.
  12. Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: The newly developed COMCOLD index. J Clin Epidemiol. 2014;67:904–911.
  13. Niżankowska-Mogilnicka E, Mejza F, Biust AS, et al. Prevalence of COPD and tobacco smoking in Małopolska region – results from the BOLD study in Poland. Pol Arch Med Wewn. 2007;117:402–410.
  14. Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–338.
  15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
  16. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–586.
  17. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012.
  18. Lahousse L, Niemeijer MN, van den Berg ME, et al. Chronic obstructive pulmonary disease and sudden cardiac death: The Rotterdam study. Eur Heart J. 2015;36:1754–1761.
  19. Sin DD, Man MF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2:8–11.
  20. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107:376–384.
  21. Lange P, Mogelvang R, Marott JL, et al. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010;7:5–10.
  22. Martinez CH, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPD gene cohort. Respir Res. 2014;15:62. doi: 10.1186/1465-9921-15-62
  23. Liang B, Wang M, Yi Q, et al. Association of gastroesophageal reflux disease risk with exacerbations of chronic obstructive pulmonary disease. Dis Esophagus. 2013;26:557–560.
  24. Shah SH, Sonawane P, Nahar P, et al. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013;30:108–112.
  25. Aparna A. Pulmonary function tests in type 2 diabetics and non-diabetic people – a comparative study. J Clin Diagn Res. 2013;7:1606–1608.
  26. Gläser S, Krüger S, Merkel M, Bramlage P, Herth FJ. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. Respiration. 2015;89:253–264.
  27. McGhan R, Radcliff T, Fish R, et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132:1748–1755.
  28. Greenberg-Dotan S, Reuveni H, Tal A, et al. Increased prevalence of obstructive lung disease in patients with obstructive sleep apnea. Sleep Breath. 2014;18:69–75.
  29. Shiina K, Tomiyama H, Takata Y, et al. Overlap syndrome: Additive effects of COPD on the cardiovascular damages in patients with OSA. Respir Med. 2012;106:1335–1341.
  30. Chen SJ, Liao WC, Huang KH, et al. Chronic obstructive pulmonary disease and allied conditions is a strong independent risk factor for osteoporosis and pathologic fractures: A population-based cohort study. QJM. 2015;108:633–640.
  31. McGarvey L, Lee AJ, Roberts J, et al. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med. 2015;109:228–237.
  32. Sanchez-Salcedo P, Berto J, de-Torres JP, et al. Lung cancer screening: Fourteen-year experience of the Pamplona early detection program (P-IELCAP). Arch Bronconeumol. 2015;51:169–176.
  33. Yohannes AM, Ershler WB. Anemia in COPD: A systematic review of the prevalence, quality of life, and mortality. Respir Care. 2011;56:644–652.
  34. Gaddam S, Gunukula SK, Lohr JW, et al. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. BMC Pulm Med. 2016;16:158. doi: 10.1186/s12890-016-0315-0
  35. Terzano C, Romani S, Paone G, et al. COPD and thyroid dysfunctions. Lung. 2014;192:103–109.